COMP <GO>
PFE vs VRTX // EV/EBITDA & P/E VALUATION
Pfizer Inc. (NYSE) VS. Vertex Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: PFE 6
— VRTX 7
▲ EV/EBITDA & P/E VALUATION LEADER: PFE
LAST: $30.52 (+1.90%) • MKT CAP: $170.71B
valuation
19.7x
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
valuation
29.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. VRTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | VRTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 86.20% | -11.90 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 20.00% | -14.90 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.7x | 29.6x | -9.90 | PFE | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 2.33% | +2.99 | PFE | /fcf-yield <GO> |
| Operating Margin | 15.10% | 34.80% | -19.70 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 32.90% | -20.50 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 8.90% | -10.50 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 13.86 | -11.76 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 57.7 | +0.80 | PFE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.02 | +0.03 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 32.2x | -11.70 | PFE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $136.87B | $33.84B | PFE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | VRTX REV | PFE GROSS % | VRTX GROSS % | PFE FCF | VRTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $12.00B | 74.3% | 86.2% | $9.07B | $3.19B |
| FY 2024 | $63.63B | $11.02B | 71.9% | 86.1% | $9.84B | -$790.3M |
| FY 2023 | $50.91B | $9.87B | — | — | $6.41B | $3.09B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
VRTX // BETA 1.02